Skip to content

Open calls · Research grant · Medicine

Exploratory Grants in Cancer Control (R21 Clinical Trial Optional)

National Institutes of Health · Cancer Cause and Prevention Research · PA-25-253

Go to the funder’s page
665days left

Deadlines

  • 7 Sep 2028 Deadline in 665 days

Who can apply

Where the work is done
United States
Who applies
An organisation

About the call

This funding opportunity announcement (FOA) encourages the submission of exploratory/developmental research grant (R21) applications that focus on different aspects of cancer control by modifying behavior, screening, and understanding etiologic factors contributing to the development of cancer, and developing ways to control cancer. The overarching goal is to provide support to promote the early and conceptual stages of research efforts on novel scientific ideas that have the potential to substantially advance population-based cancer research, such as the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (epidemiologic, biomedical, behavioral, health care delivery or clinical).

Text from the funder (US federal government, public domain).

Conditions in full

Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

We sort calls into fields, career stages and countries automatically. Always check the conditions on the funder’s page before you apply.

Discussion

Applying too? Looking for partners? Ask here.